Navigation Links
Larry Klayman files lawsuit against Former FDA commissioner Hamburg, Johnson & Johnson and others sued for alleged racketeering and other claims over dangerous drug Levaquin
Date:1/19/2016

WASHINGTON, Jan. 19, 2016 /PRNewswire/ -- Today, Larry Klayman, counsel for individual plaintiffs who were seriously harmed by the dangerous drug Levaquin, brought suit in the U.S. District Court for the District of Columbia alleging violations of the Racketeering and Corrupt Organizations Act ("RICO"), the Lanham Act, and a variety of common law torts. http://www.larryklayman.com/pdf/160119-Final Filed Levaquin Complaint .pdf

According to Klayman, "Obama administration appointee, former FDA Commissioner Dr. Margaret Hamburg, is at the heart of this scandal, and her husband Peter Brown, co-CEO of Renaissance Technologies, L.L.C., a major New York hedge fund. While Dr. Hamburg was head of the FDA, her husband profited enormously from as much as half a billion dollars in Johnson & Johnson stock, the maker of Levaquin, held by Renaissance Technologies."

Levaquin is a drug intended to treat a range of infections, including routine sinus, skin and urinary tract infections.

The complaint alleges Dr. Hamburg and her husband and others at Renaissance Technologies, L.L.C., conspired with Johnson & Johnson and other defendants to suppress information about Levaquin's harmful effects. "To reveal it would have not only harmed Johnson & Johnson's profits, but invite significant lawsuits, driving Johnson & Johnson stock price downward, thereby financially harming Dr. Hamburg, her husband and Renaissance Technologies' profits. Plaintiffs were unwitting victims, suffering from a variety of medical conditions, some of which were just recently disclosed at an FDA Advisory Committee Hearing November 5, 2015.

The complaint can be found at www.larryklayman.com and its allegations speak for themselves.

Klayman called it "a major scandal affecting the health plaintiffs and thousands of others. Defendants allegedly reaped large financial gains and profits at the expense of my clients. The entire sad episode exemplifies how some in private industry allegedly conspire and act with Washington D.C. public officials to greedily line their pockets, leaving everyone else to be damned."

"The complaint asks for millions of dollars in damages and justice," said Klayman, founder of Judicial Watch and Freedom Watch, and a former federal prosecutor who, during his tenure at the U.S. Department of Justice, not coincidentally prosecuted on behalf of the Food and Drug Administration and other federal agencies, as well as serving on the trial team that, in a landmark antitrust case, broke up the monopoly of AT&T.

For information, contact daj142182@gmail.com.

Media contact: Adrienne Mazzone 561-750-9800 x2270; amazzone@transmediagroup.com.

 


'/>"/>
SOURCE Larry Klayman
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. Impax Announces Resignation of Larry Hsu, Ph.D. from Board of Directors
2. Larry D. Altstiel, M.D., Ph.D. Joins Neurotrope Board of Directors
3. MabVax Therapeutics Files IND for a Phase I Clinical Trial with 89Zr-HuMab-5B1
4. Medical Implants Market 10 Major Company Profiles and 2021 Forecasts
5. Lopez McHugh files Invokana Lawsuit Alleging Diabetic Ketoacidosis Injury
6. Relmada Therapeutics Files Federal Lawsuit Against Laidlaw & Company and its Principals Matthew Eitner and James Ahern to Protect Interests of Relmada Stockholders
7. Spinal Fusion Market Forecast to 2020 With 13 Company Profiles
8. MabVax Therapeutics Files IND for Phase I Clinical Trial with HuMab 5B1 as a Therapeutic for Pancreatic Cancer
9. Global Molecular Diagnostics Market 2016: Emerging Technologies and Strategic Profiles of Leading Suppliers
10. Acute Lymphocytic/Lymphoblastic Leukemia Market: 4% CAGR Forecast to 2019, Company Profiles and More
11. Germany Hospital Coagulation Testing Market 2016 - Profiles of Major Current and Emerging Suppliers, Including their Sales and Market Shares
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/11/2019)... ... 11, 2019 , ... Abilene Christian University (ACU) is offering an alternative entry ... online BSN to DNP program pathway is meant to serve as a fast track ... degree to a Doctor of Nursing Practice degree. , Traditionally, a student would ...
(Date:9/11/2019)... ... September 11, 2019 , ... LifePod® ... innovator HomeThrive has selected LifePod’s voice-first service for rollout to an initial 100 ... over the age of 50, demand has steadily increased for solutions that both ...
(Date:9/11/2019)... , ... September 11, 2019 , ... ... today announced Orion Pharma, a globally operating Finnish pharmaceutical company, has licensed Genedata ... system, and other medical indications. , “As part of our strategy to ...
Breaking Medicine Technology:
(Date:9/17/2019)... ... September 17, 2019 , ... ... Warriors , with the goal of providing resources to assist researchers and encourage ... a progressive disease causing abnormal iron deposits in the brain. , BPAN ...
(Date:9/17/2019)... ... September 17, 2019 , ... ... day on Pacifica's Lambert Campus, 249 Lambert Road, Carpinteria, CA. The day ... Clinical Psychology, Counseling Psychology, and Mythological Studies. Program Faculty will host program-specific ...
(Date:9/12/2019)... ... September 12, 2019 , ... Donaldson ... national scale in two recent and well-renowned listing publications, the Inc. 5000 and ... for the 2019 year. , Dr. Jeffrey Donaldson, CEO and owner of ...
(Date:9/11/2019)... ... ... A September 2 article on CBS News details a new ... to suffer heart attacks, strokes, kidney failure, and heart disease versus a control group ... specialists Dr. Feiz and Associates says the study adds further evidence to an overwhelming ...
(Date:9/11/2019)... N.J. (PRWEB) , ... September 11, 2019 , ... ... management, will exhibit at the 2019 AHIMA Health Data and Information Conference in ... to stop by booth #505 to learn more about GRM’s healthcare information ...
Breaking Medicine News(10 mins):